Investors and Media



Sangamo is a clinical stage biopharmaceutical company focused on the research, development and commercialization of engineered DNA-binding proteins as novel therapeutics to treat unmet medical needs. We are worldwide leaders in developing zinc finger DNA-binding proteins (ZFPs) for therapeutic gene regulation and modification. Our ZFP technology platform has multiple applications in:

  • Human Therapeutics
  • High-value Research Tools
  • Transgenic Animals
  • Cell-line Engineering for Protein Manufacturing
  • Plant Agriculture

View all »   RSSRecent Releases

Jul 29, 2015
Sangamo BioSciences Announces Second Quarter 2015 Conference Call and Webcast

Jun 17, 2015
Sangamo BioSciences Announces Presentation At The 2015 JMP Securities Life Sciences Conference


View all »Events & Presentations

Aug 5, 2015 at 5:00 PM ET
Sangamo's Quarterly Teleconference

Stock Quote

Ticker:
SGMO
Exchange:
NASDAQ
Price:
9.15
Change:
+ 0.35
Day High:
9.30
Day Low:
8.71
Volume:
647,900
4:00 PM ET on Jul 31, 2015

Shareholder Tools